$\require{mediawiki-texvc}$
  • 검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
  • 검색연산자
검색도움말
검색연산자 기능 검색시 예
() 우선순위가 가장 높은 연산자 예1) (나노 (기계 | machine))
공백 두 개의 검색어(식)을 모두 포함하고 있는 문서 검색 예1) (나노 기계)
예2) 나노 장영실
| 두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색 예1) (줄기세포 | 면역)
예2) 줄기세포 | 장영실
! NOT 이후에 있는 검색어가 포함된 문서는 제외 예1) (황금 !백금)
예2) !image
* 검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색 예) semi*
"" 따옴표 내의 구문과 완전히 일치하는 문서만 검색 예) "Transform and Quantization"

통합검색

도움말도움말
상세검색 다국어 입력

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

특허 상세정보

MyON담기
내보내기 페이스북 공유 카카오톡 공유

Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated

특허상세정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판) G01N-033/53    C07K-007/04    C07K-014/705    C07K-014/82   
미국특허분류(USC) 435/072.4 ; 435/071 ; 435/072 ; 530/350 ; 530/300
출원번호 US-0414417 (1995-03-31)
발명자 / 주소
출원인 / 주소
대리인 / 주소
    Seed and Berry LLP
인용정보 피인용 횟수 : 80  인용 특허 : 8
초록
▼

Methods for the detection, monitoring and treatment of malignancies in which the HER-2/neu oncogene is associated are disclosed. Detection of specific T cell activation (e.g., by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2/neu protein, or detection of immunocomplexes formed between the HER-2/neu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2/neu oncogene is associated. The present invention also discloses methods and compositions, including peptides, ...

대표
청구항

[ We claim:] [1.] A method of screening for the presence of a malignancy in a warm-blooded animal, wherein a HER-2/neu oncogene is associated with the malignancy, comprising the steps of:(a) obtaining peripheral blood cells from said warm-blooded animal;(b) incubating said cells with HER-2/neu protein; and(c) detecting the presence or absence of specific activation of CD4.sup.+ T cells, wherein the presence of specific activation is indicative of the presence of malignancy.

이 특허에 인용된 특허 (8)

  1. Rubenstein Kenneth Edward (Palo Alto CA) Leute Richard K. (Sunnyvale CA). Antibody steric hindrance immunoassay with two antibodies. USP1976013935074.
  2. Uzgiris Egidijus E. (Schenectady NY). Electrophoretic method of detecting antigen-antibody reaction. USP1976103984533.
  3. Gordon Julian (Arlesheim CHX) Staehelin Theophil (Arlesheim CHX) Towbin Harry (Allschwil CHX). Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays. USP1984064452901.
  4. Ullman Edwin F. (Atherton CA) Schwarzberg Moshe (Palo Alto CA). Fluorescence quenching with immunological pairs in immunoassays. USP1976123996345.
  5. Cheever, Martin A.; Peace, David J.. Immune reactivity to expressed activated oncogenes for diagnosis of malignancy. USP1994065320947.
  6. Maggio Edward T. (Redwood City CA) Wife Richard L. (Sittingbourne CA GB2) Ullman Edwin F. (Atherton CA). Reagents and method employing channeling. USP1980114233402.
  7. Piasio ; Roger N. ; Ryan ; James W. ; Woiszwillo ; James E.. Reverse sandwich immunoassay. USP1978074098876.
  8. Miles Laughton E. M. (Stanford CA). Universal reagent 2-site immunoradiometric assay using labelled anti (IgG). USP1977074034074.

이 특허를 인용한 특허 피인용횟수: 80

  1. Fendly,Brian M.. Anti-ErbB2 antibodies. USP2008057371376.
  2. Kaumaya, Pravin. Chimeric peptides comprising HER-2 B-cell epitopes and T-helper epitopes. USP2013068470333.
  3. Kaumaya, Pravin. Chimeric peptides comprising HER-2 B-cell epitopes and Tcell helper epitopes. USP2016099452204.
  4. Stojdl, David F.. Compositions and methods for glioblastoma treatment. USP2016069364532.
  5. Shen, Jikui; Kelnar, Kevin; Shelton, Jeffrey; Brown, David; Campochiaro, Peter. Compositions and methods related to miRNA modulation of neovascularization or angiogenesis. USP2016069365852.
  6. Shen, Jikui; Kelnar, Kevin; Shelton, Jeffrey; Brown, David; Campochiaro, Peter. Compositions and methods related to miRNA modulation of neovascularization or angiogenesis. USP2012098258111.
  7. Mass, Robert D.. Detection of ErbB2 gene amplification to increase the likelihood of the effectiveness of ErbB2 antibody breast cancer therapy. USP2011087993834.
  8. Baughman, Sharon A.; Shak, Steven. Dosages for treatment with anti-ErbB2 antibodies. USP2003096627196.
  9. Baughman,Sharon A.; Shak,Steven. Dosages for treatment with anti-ErbB2 antibodies. USP2008057371379.
  10. Mass, Robert D.. Gene detection assay for improving the likelihood of an effective response to a HER2 antibody cancer therapy. USP2013058440402.
  11. Mass, Robert D.. Gene detection assay for improving the likelihood of an effective response to a HER2 antibody cancer therapy. USP2011128076066.
  12. Mass, Robert D.. Gene detection assay for improving the likelihood of an effective response to an EGFR antagonist cancer therapy. USP2013118592152.
  13. Kirn, David; Bell, John; Breitbach, Caroline; Moon, Anne; Hwang, Tae-Ho; Lee, Yu Kyoung; Kim, Mi-kyung. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus. USP2018039919047.
  14. Cheever, Martin A.; Gheysen, Dirk. HER-2/neu fusion proteins. USP2013108568733.
  15. Cheever,Martin A.; Gheysen,Dirk. HER-2/neu fusion proteins. USP2007047198920.
  16. Cheever,Martin A.; Gheysen,Dirk. HER-2/neu fusion proteins. USP2008057375091.
  17. Cheever,Martin A.; Gheysen,Dirk. Her-2/neu fusion proteins. USP2007067229623.
  18. Adams, Camellia W.; Presta, Leonard G.; Sliwkowski, Mark. Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodies. USP2009057537931.
  19. Adams, Camellia W.; Presta, Leonard G.; Sliwkowski, Mark. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies. USP2011017862817.
  20. Sliwkowski, Mark. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies. USP2005096949245.
  21. Pravin, Kaumaya. Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use. USP2016119504738.
  22. McGinity, Michael J.; Zhang, Feng; Floyd, John R.; McGinity, James W.. Implant compositions for the unidirectional delivery of therapeutic compounds to the brain. USP2018059956172.
  23. Brown, David; Conrad, Rick; Devroe, Eric; Goldrick, Marianna; Keiger, Kerri; Labourier, Emmanuel; Moon, Ivonne; Powers, Patricia; Shelton, Jeffrey; Shingara, Jaclyn. Method and compositions involving microRNA. USP2013068465914.
  24. Kirn, David; Thorne, Steve H.. Methods and compositions concerning poxviruses and cancer. USP2012128329164.
  25. Kirn, David; Thorne, Steve H.. Methods and compositions concerning poxviruses and cancer. USP2015038986674.
  26. Brown, David; Conrad, Rick; Devroe, Eric; Goldrick, Marianna; Keiger, Kerri; Labourier, Emmanuel; Moon, Ivonne; Powers, Patricia; Shelton, Jeffrey; Shingara, Jaclyn. Methods and compositions involving MicroRNA. USP20180810047388.
  27. Brown, David; Keiger, Kerri; Labourier, Emmanuel; Shelton, Jeffrey; Shingara, Jaclyn. Methods and compositions involving MicroRNA. USP2011088003320.
  28. Adai, Alex; Szafransak-Schwarzbach, Anna; Andruss, Bernard; Hahn, Stephan Albrecht. Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease. USP2017059644241.
  29. Brown, David; Ford, Lance; Cheng, Angie; Jarvis, Rich; Byrom, Mike; Ovcharenko, Dmitriy; Devroe, Eric; Kelnar, Kevin. Methods and compositions involving miRNA and miRNA inhibitor molecules. USP2016079382537.
  30. Brown, David; Ford, Lance; Cheng, Angie; Jarvis, Rich; Byrom, Mike; Ovcharenko, Dmitriy; Devroe, Eric; Kelnar, Kevin. Methods and compositions involving miRNA and miRNA inhibitor molecules. USP2016119506061.
  31. Brown, David; Ford, Lance; Cheng, Angie; Jarvis, Rich; Byrom, Mike; Ovcharenko, Dmitriy; Devroe, Eric; Kelnar, Kevin. Methods and compositions involving miRNA and miRNA inhibitor molecules. USP2016099447414.
  32. Brown, David; Ford, Lance; Cheng, Angie; Jarvis, Rich; Byrom, Mike; Ovcharenko, Dmitriy; Devroe, Eric; Kelnar, Kevin. Methods and compositions involving miRNA and miRNA inhibitor molecules. USP2012058173611.
  33. Brown, David; Ford, Lance; Cheng, Angie; Jarvis, Rich; Byrom, Mike; Ovcharenko, Dmitriy; Devroe, Eric; Kelnar, Kevin. Methods and compositions involving miRNA and miRNA inhibitor molecules. USP2014078765709.
  34. Brown, David; Ford, Lance; Cheng, Angie; Jarvis, Rich; Byrom, Mike; Ovcharenko, Dmitriy; Devroe, Eric; Kelnar, Kevin. Methods and compositions involving miRNA and miRNA inhibitor molecules. USP2015069051571.
  35. Brown, David; Ford, Lance; Cheng, Angie; Jarvis, Rich; Byrom, Mike; Ovcharenko, Dmitriy; Devroe, Eric; Kelnar, Kevin. Methods and compositions involving miRNA and miRNA inhibitor molecules. USP2015069068219.
  36. Brown, David; Ford, Lance; Cheng, Angie; Jarvis, Rich; Byrom, Mike; Ovcharenko, Dmitriy; Devroe, Eric; Kelnar, Kevin. Methods and compositions involving miRNA and miRNA inhibitor molecules. USP2013108563708.
  37. Brown, David; Ford, Lance; Cheng, Angie; Jarvis, Rich; Byrom, Mike; Ovcharenko, Dmitriy; Devroe, Eric; Kelnar, Kevin. Methods and compositions involving miRNA and miRNA inhibitor molecules. USP2011118058250.
  38. Brown, David; Ford, Lance; Cheng, Angie; Jarvis, Rich; Byrom, Mike; Ovcharenko, Dmitriy; Devroe, Eric; Kelnar, Kevin. Methods and compositions involving miRNA and miRNA inhibitor molecules. USP2015028946177.
  39. Brown, David; Conrad, Rick; Devroe, Eric; Goldrick, Marianna; Keiger, Kerri; Labourier, Emmanuel; Moon, Ivonne; Powers, Patricia; Shelton, Jeffrey; Shingara, Jaclyn. Methods and compositions involving microRNA. USP2013108568971.
  40. Brown, David; Keiger, Kerri; Labourier, Emmanuel; Shelton, Jeffrey; Shingara, Jaclyn. Methods and compositions involving microRNA. USP2011027888010.
  41. Qiu, Zhiyong; Bot, Adrian Ion. Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma. USP2014038674081.
  42. Qiu, Zhiyong; Bot, Adrian Ion. Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma. USP2011087999088.
  43. Roth, Mark B.; Morrison, Mike; Blackstone, Eric; Miller, Dana. Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms. USP2014098822535.
  44. Beaudenon-Huibregtse, Sylvie; Labourier, Emmanuel; Elizondo, Laura. MicroRNAs differentially expressed in cervical cancer and uses thereof. USP2015079080215.
  45. Beaudenon-Huibregtse, Sylvie; Labourier, Emmanuel; Elizondo, Laura. Micrornas differentially expressed in cervical cancer and uses thereof. USP2013018361714.
  46. Bell, John C.; Stojdl, David F.. Oncolytic rhabdovirus. USP2015069045729.
  47. Bell, John C.; Stojdl, David F.. Oncolytic rhabdovirus. USP2018029896664.
  48. Kirn, David. Oncolytic vaccinia virus cancer therapy. USP2015038980246.
  49. Kirn, David; Breitbach, Caroline. Oncolytic vaccinia virus combination cancer therapy. USP2014068747837.
  50. Kirn, David; Breitbach, Caroline. Oncolytic vaccinia virus combination cancer therapy. USP2015119180151.
  51. Antonia, Scott; Gabrilovich, Dmitry I.; Chada, Sunil; Menander, Kerstin B.. P53 vaccines for the treatment of cancers. USP2014038668905.
  52. Kaumaya, Pravin. Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein. USP2012028110657.
  53. Kaumaya, Pravin T. P.. Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein. USP2010027666430.
  54. Kaumaya,Pravin T. P.; Stevens,Vernon C.; Triozzi,Pierre L.. Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein. USP2006067060284.
  55. Andya, James; Cleland, Jeffrey L.; Hsu, Chung C.; Lam, Xanthe M.; Overcashier, David E.; Shire, Steven J.; Yang, Janet Yu-Feng; Wu, Sylvia Sau-Yan. Protein formulation. USP2016039283273.
  56. Andya, James; Cleland, Jeffrey L.; Hsu, Chung C.; Lam, Xanthe M.; Overcashier, David E.; Shire, Steven J.; Yang, Janet Yu-Feng; Wu, Sylvia Sau-Yan. Protein formulation. USP2010037682609.
  57. Andya, James; Cleland, Jeffrey L.; Hsu, Chung C.; Lam, Xanthe M.; Overcashier, David E.; Shire, Steven J.; Yang, Janet Yu-Feng; Wu, Sylvia Sau-Yan. Protein formulation. USP2004026685940.
  58. Andya,James; Cleland,Jeffrey L.; Hsu,Chung C.; Lam,Xanthe M.; Overcashier,David E.; Shire,Steven J.; Yang,Janet Yu Feng; Wu,Sylvia Sau Yan. Protein formulation. USP2006067060268.
  59. Cleland, Jeffrey L.; Hsu, Chung C.; Lam, Xanthe M.; Overcashier, David E.; Yang, Janet Yu-Feng. Protein formulation. USP2004116821515.
  60. Kelnar, Kevin; Brown, David. Synthetic mimics of miR-34. USP2016069371526.
  61. Kelnar, Kevin; Brown, David. Synthetic mimics of miR-34. USP2013118586727.
  62. Kirn, David. Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses. USP2015119180149.
  63. Andya, James; Hsu, Chung C.; Shire, Steven J.; Wu, Sylvia Sau-Yan. Treating a mammal with a formulation comprising an antibody which binds IgE. USP2015119180189.
  64. Sliwkowski,Mark X.. Treating prostate cancer with anti-ErbB2 antibodies. USP2006057041292.
  65. Baughman, Sharon A.; Shak, Steven. Treatment with anti-ErbB2 antibodies. USP20181210160811.
  66. Hellmann, Susan D.. Treatment with anti-ErbB2 antibodies. USP2010127846441.
  67. Hellmann, Susan D.. Treatment with anti-ErbB2 antibodies. USP2012118309087.
  68. Hellmann, Susan D.. Treatment with anti-ErbB2 antibodies. USP2013048425908.
  69. Hellmann, Susan D.. Treatment with anti-ErbB2 antibodies. USP2011128075892.
  70. Hellmann, Susan D.. Treatment with anti-ErbB2 antibodies. USP2014028642036.
  71. Paton, Virginia E.; Shak, Steven; Hellmann, Susan D.. Treatment with anti-ErbB2 antibodies. USP2011027892549.
  72. Sliwkowski, Mark. Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs. USP2009117618631.
  73. Adams,Camellia W.; Presta,Leonard G.; Sliwkowski,Mark. Treatment with anti-ErbB2 antibodies and anti-hormonal compounds. USP2009037498030.
  74. Adams,Camellia W.; Presta,Leonard G.; Sliwkowski,Mark. Treatment with anti-ErbB2 antibodies and chemotherapeutic agents. USP2009027485302.
  75. Adams,Camellia W.; Presta,Leonard G.; Sliwkowski,Mark. Treatment with anti-ErbB2 antibody combinations. USP2009037501122.
  76. Chada, Sunil. Use of MDA-7 to inhibit pathogenic infectious organisms. USP2011108034790.
  77. Zielinski,Christoph; Scheiner,Otto; Jensen Jarolim,Erika; Breiteneder,Heimo; Pehamberger,Hubert. Vaccine against cancer diseases that are associated with the her-2/neu oncogene. USP2008037348010.
  78. Zielinski,Christoph; Scheiner,Otto; Jensen Jarolim,Erika; Breiteneder,Heimo; Penamberger,Hubert. Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells. USP2007017166694.
  79. Vandepapeliere, Pierre. Vaccine compositions comprising a saponin adjuvant. USP20181210143745.
  80. Vandepapeliere, Pierre. Vaccine compositions comprising a saponin adjuvant. USP20180810039823.

IPC 상위 출원인